

Cover Story
																																	News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink. 
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
 - Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
 - Duke brain cancer researcher Kyle Walsh named director of NIEHS
 - Cancer centers adapt to life without site visits as NIH changes CCSG review
 - Trump cuts IVF drug deal with Merck in exchange for tariff exemption
 - Jonathan Licht named president, chief scientific officer at Van Andel Institute
 
            

















